Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Moody's Investors Service – the credit rating arm of Moody's Corp. ( MCO - Analyst Report ) – has placed the ratings of Zions Bancorp ( ZION - Analyst Report ) and its affiliates on review for a likely upgrade. The main reason behind the possible rise in rating is the company’s plummeting asset concentrations.
Currently, Zions’ subordinated debt is rated ‘B1.’ Moreover, its main operating bank, Zions First National Bank, has a financial strength rating of ‘D+’, which reflects baseline credit assessment of ‘ba1.’ The bank’s financial strength rating of ‘D+’ was affirmed, but its baseline credit assessment of ‘ba1’ will be appraised for promotion.
The long-term deposit rating of Zions bank is ‘Ba1.’ The short-term Not-Prime ratings of Zions bank and other bank subsidiaries were also placed on review. The short-term Not-Prime ratings of Zions were affirmed and are not under review.
Zions’ efforts to reduce asset concentration, which has resulted in lower credit costs and improved profitability, has prompted Moody’s to review its ratings for possible raise. The lower asset concentration stemmed from reductions in construction lending portion of its commercial real estate (CRE) portfolio and improvement in its capital base.
Further, Moody’s will evaluate the efforts that Zions will undertake to ensure that there is no rebuilding of asset concentrations in its portfolio. In addition, Moody’s will assess steps taken by the company to mitigate the concentration risk emanating from its high dependence on net interest income. The review will also focus on Zions' expected long-term performance compared with its peers, particularly due to its franchise positioning.
Moody’s has also placed the long-term ratings of Regions Financial Corp. (RF) on review. Currently, Regions’ holds long-term rating of ‘Ba3’, which is three notches below the investment grade. The company’s efforts of de-risking its profile by lessening exposure to risky commercial real estate and home equity loans, along with strengthening internal controls, has prompted Moody’s to place its ratings on review.
Further, the company’s efforts to reduce nonperforming assets and tackling the persistent low interest rate environment to keep the top-line growth intact will be supervised.
If Moody’s upgrades Zions’ ratings, it will surely boost investors’ confidence in the stock. Nevertheless, we remain concerned about the prevailing low interest rate environment, sluggish economic growth, the company’s asset-sensitive balance sheet and regulatory pressures.
Zions currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Considering the fundamentals, we also maintain a long-term Neutral’ recommendation on the stock.
Read the full reports :
Analyst Report on MCO
Analyst Report on ZION